| NCT ID | NCT06500403 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Condition | Non-Cirrhotic Portal Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-02-28 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-02-28 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients treated with platinum-based chemotherapy drugs have the probability of developing PSVD. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guiding value in the diagnosis and prognosis of PSVD. Many studies have shown that liver and spleen stiffness have high accuracy in diagnosis and prognosis. The purpose of this study is to evaluate the efficacy of the combination of liver and spleen stiffness in the diagnosis of PSVD and to search for effective biomarkers for the diagnosis of PSVD through a single-center, prospective, observational study.
Eligibility Criteria
Inclusion Criteria: 1. Received platinum chemotherapy for organ tumors; 2. Ages 18-80; 3. sign the informed consent voluntarily. Exclusion Criteria: 1. Liver pathology suggested cirrhosis; 2. Underwent liver transplantation; 3. Combined with hepatocellular carcinoma exceeding Milan criteria; 4. Complicated with severe heart, kidney, or lung failure; 5. Pregnant or lactating women; 6. Data is seriously missing; 7. Patients were judged not suitable for participation in this study by the researchers.
Contact & Investigator
Xiaofeng Zhang
PRINCIPAL INVESTIGATOR
Nanfang Hospital, Southern Medical University
Frequently Asked Questions
Who can join the NCT06500403 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Non-Cirrhotic Portal Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06500403 currently recruiting?
Yes, NCT06500403 is actively recruiting participants. Contact the research team at 1282614092@qq.com for enrollment information.
Where is the NCT06500403 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06500403 clinical trial?
NCT06500403 is sponsored by Nanfang Hospital, Southern Medical University. The principal investigator is Xiaofeng Zhang at Nanfang Hospital, Southern Medical University. The trial plans to enroll 1,000 participants.